Loading organizations...

§ Private Profile · Malvern, PA, USA
Neuronetics is a technology company.
Neuronetics is committed to improving quality of life for people suffering from psychiatric disorders through non-drug, non-invasive treatments. Their NeuroStar® Advanced Therapy is a leading TMS treatment for depression.
Neuronetics has raised $168.0M across 7 funding rounds.
Neuronetics has raised $168.0M in total across 7 funding rounds.
Neuronetics has raised $168.0M in total across 7 funding rounds.
Neuronetics's investors include Access Biotechnology, Atlas Venture, Borealis Ventures, Flagship Ventures, GE Ventures, InterWest, SR One, Vivo Capital, Wildcat Ventures, Timothy A. Springer, Accuitive Medical Ventures, Rubal Bedi.
Neuronetics, Inc. (NASDAQ: STIM) is a commercial-stage medical technology company specializing in non-invasive neuromodulation treatments for psychiatric and neurological disorders, primarily major depressive disorder (MDD).[1][2][4] Its flagship product, the NeuroStar® Advanced Therapy System, delivers transcranial magnetic stimulation (TMS) using magnetic pulses to target brain areas involved in mood regulation, offering a drug-free alternative to medications or electroconvulsive therapy (ECT) with fewer side effects.[1][4][5] The company serves healthcare providers, including private practices and institutions, as well as patients via its Greenbrook treatment centers, addressing unmet needs in mental health for over 229,000 patients through more than 8.2 million treatments delivered.[3][5] Neuronetics demonstrates growth through expansions like FDA clearances for adolescent MDD (ages 15-21 in March 2024), OCD, and anxious depression, alongside programs like Better Me Provider (BMP) and tools such as TrakStar for outcome optimization.[1][2][7]
Founded in 2003, Neuronetics emerged from a vision to provide non-invasive, drug-free options for conditions like MDD and obsessive-compulsive disorder (OCD).[1][2] The company's roots lie in advancing neuromodulation technology, with early focus on developing the NeuroStar TMS system, which gained FDA clearance and built credibility through rigorous clinical research.[1][4] Pivotal moments include launching TrakStar in 2021—a cloud-based platform for data analysis to improve patient outcomes—and securing FDA expansions, such as adolescent treatment in 2024 and OCD/anxious depression protocols via software updates.[1][2][7] This evolution reflects a patient-centric shift toward broader neurohealth applications, supported by partnerships with U.S. healthcare providers and over 300 million insured lives covering NeuroStar.[1][5]
Neuronetics stands out in the TMS market through proprietary innovations and clinical backing:
Neuronetics rides the neuromodulation wave in mental health tech, where demand surges for non-pharmacological treatments amid rising MDD prevalence—a recurrent condition affecting millions, with many unresponsive to drugs.[1][2][3] Timing aligns with post-pandemic mental health crises, insurance expansions (covering >300M lives), and FDA nods for adolescents/OCD, tapping underserved markets like youth and comorbid anxiety.[1][5][7] Favorable forces include reimbursement growth, clinical validation over rivals, and tech scalability (e.g., software updates for new indications).[2][4] The company influences the ecosystem by standardizing TMS via BMP/TrakStar, partnering with providers, and driving innovation—expanding from MDD to broader neurohealth, normalizing office-based neuromodulation as viable alternatives to invasive therapies.[1][4][5]
Neuronetics is poised for expansion with R&D targeting new indications, geographic reach, and protocol innovations like Theta Burst, building on recent FDA wins and 7.1M+ treatments.[1][3][5] Trends like AI-enhanced outcomes (via TrakStar), adolescent/OCD demand, and insurance parity will propel growth, despite a negative P/E (-1.62) signaling investment phase ahead of March 2026 earnings.[1][2] Its influence may evolve as the TMS leader, potentially dominating neuromodulation by integrating data-driven personalization and multi-disorder versatility—renewing lives in an era prioritizing accessible mental health tech.[4][5] This positions Neuronetics as a pivotal player transforming neurohealth from vision to mainstream reality.
Neuronetics has raised $168.0M across 7 funding rounds. Most recently, it raised $15.0M Series G in June 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2017 | $15M Series G | — | Access Biotechnology, Atlas Venture, Borealis Ventures, Flagship Ventures, GE Ventures, InterWest, SR ONE, Vivo Capital, Wildcat Ventures, Timothy A. Springer, Accuitive Medical Ventures, Rubal Bedi, Industry Ventures, Interwest Partners, Investor Growth Capital, KBL Healthcare Ventures, NEW Leaf Venture Partners, ONSET Ventures, Pfizer, Polaris Partners, Three Arch Partners | Announced |
| Apr 1, 2015 | $34M Series F | — | Access Biotechnology, Atlas Venture, GE Ventures, InterWest, SR ONE, Wildcat Ventures, Timothy A. Springer | Announced |
| May 1, 2011 | $30M Series E | Kevin Bitterman | Access Biotechnology, Atlas Venture, Borealis Ventures, Flagship Ventures, GE Ventures, InterWest, SR ONE, Vivo Capital, Wildcat Ventures, Timothy A. Springer, Interwest Partners, Investor Growth Capital, NEW Leaf Venture Partners, ONSET Ventures, Quaker Partners, Three Arch Partners | Announced |
| Oct 1, 2009 | $30M Series D | — | Access Biotechnology, Atlas Venture, Borealis Ventures, Flagship Ventures, GE Ventures, InterWest, Vivo Capital, Wildcat Ventures | Announced |
| Aug 1, 2006 | $35M Series C | — | Access Biotechnology, Atlas Venture, Borealis Ventures, Flagship Ventures, GE Ventures, InterWest, Vivo Capital, Wildcat Ventures | Announced |
| Mar 1, 2005 | $9M Series B | — | Access Biotechnology, Atlas Venture, Borealis Ventures, Flagship Ventures, GE Ventures, InterWest, Vivo Capital, Wildcat Ventures | Announced |
| Apr 1, 2003 | $15M Series A | — | Access Biotechnology, Atlas Venture, Borealis Ventures, Flagship Ventures, GE Ventures, InterWest, Vivo Capital, Wildcat Ventures | Announced |